Genor Biopharma Holdings Ltd
06998
Company Profile
Business description
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Contact
690 Bibo Road
Room 501-02, Building 6
Pudong New District
Shanghai201203
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,136.60 | 15.10 | 0.17% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,375.36 | 22.53 | -0.05% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,694.54 | 34.53 | 0.15% |
| Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,692.03 | 3.57 | 0.05% |
| S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |